Project description
AI for rapid infectious disease diagnosis
Infectious diseases are not reliably identified due to a lack of diagnosis capacity. An increasing number of infectious agents are not easily and effectively identified without laboratory tests. As a result, physicians take into consideration the symptoms and tend to prescribe antibiotics. However, such a method does not detect whether the cause of the disease relies on bacteria or viruses, leading to inappropriate drug prescribing. The EU-funded EDAS HEALTHCARE project proposes a data-driven infectious disease diagnosis system that is the result of 5 years of research. This advanced technology is based on a combination of Big Data and machine learning algorithms and permits the diagnosis of pathogens in seconds and at a lower cost than laboratory tests.
Objective
Today, reliable diagnosis of infectious diseases is not available at the Point-Of-Care, when most needed, resulting in Antimicrobial Resistance, High Treatment Costs and Patients’ Dissatisfaction. A growing number of infectious agents – such as pneumonia, tuberculosis, and salmonellosis – with every day are becoming harder to identify and treat correctly without laboratory tests, is the main cause for a massive scale of misuse and overuse of antibiotics. Approximately 30% to 50% of antibiotic use in humans is inappropriate or even unnecessary. Due to lack of diagnosis available (Time-consuming, cost, absence of infrastructure) physicians commonly prescribe antibiotics based on symptoms. However, this approach does not allow to distinguish if the disease is caused by bacteria or viruses on which drug will work and which won't. At EDAS HEALTHCARE, patent approved technology, resulting 5 years of research, developed a data-driven infectious disease diagnosis system that enables the identification of pathogens in real-time. The use of epidemiology and location-based diagnosis combined with big-data & machine learning algorithms results in over 85% accuracy (a case study results). At a fraction of the cost of laboratory tests EDAS Healthcare can provide decision support system to all physicians at any primary care service upon the first patient encounter with the ER or GP or Telemedicine, and help instantly predict the causative agent of infectious diseases (9 different viruses and 5 different bacteria to date). Targeting the infectious disease diagnostic market worth €6Bn p.a. we offer a solution for hospitals ER, Telemedicine, Homecare, and surveillance agencies. Some of them already confirmed their interest in using our service. Within the Phase 1 project we aim at preparing plans for a wide-scale clinical trials, revise our IPR protection strategy and refine our current business model.
Fields of science
- medical and health scienceshealth sciencespublic healthepidemiology
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
12000 JERUSALEM
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.